Literature DB >> 14662555

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected.

Ofer Agid1, Shitij Kapur, Tamara Arenovich, Robert B Zipursky.   

Abstract

CONTEXT: To understand the mechanism of action of antipsychotic drugs, it is critical to recognize the time course over which these medications take effect. Current models of antipsychotic action presume a "delayed onset" of action.
OBJECTIVE: To test the delayed-onset hypothesis of antipsychotic action via a meta-analytic study. DATA SOURCES AND STUDY SELECTION: Double-masked studies that reported results from active or placebo-controlled trials of antipsychotic response during the first 4 weeks of treatment were selected. These studies were identified by searching MEDLINE, 1996 to 2001; the Cumulative Index to Nursing and Allied Health, 1982 to 2001; EMBASE, 1980 to 2001; the ACP Journal Club; the Cochrane Database of Systematic Reviews; and the Database of Abstracts of Reviews of Effectiveness. Leads from these sources were followed up by manual searches. DATA SYNTHESIS: Forty-two published studies, including 7450 patients and 119 independent response vs time curves, were identified. Reductions in total scores on the Brief Psychiatric Rating Scale and the Positive and Negative Syndrome Scale were 13.8% during week 1, 8.1% during week 2, 4.2% during week 3, and 4.7% during week 4. This pattern of "early-onset" improvement was present even after the estimated effect of placebo treatment was removed and when results were restricted to the psychotic subscales of the scales.
CONCLUSIONS: This analysis rejects the commonly held hypothesis that antipsychotic response is delayed. Rather, these findings suggest that the antipsychotic response starts in the first week of treatment and accumulates over time. Furthermore, greater improvement occurs in the first 2 treatment weeks than in the subsequent 2 treatment weeks. Proposed mechanisms of action of antipsychotic drugs need to account for this early-onset antipsychotic effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662555     DOI: 10.1001/archpsyc.60.12.1228

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  111 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

Authors:  Ofer Agid; Phillip Seeman; Shitij Kapur
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

4.  Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.

Authors:  Ee Peng Lim; Vivek Verma; Rajini Nagarajah; Gavin S Dawe
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 5.  Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Authors:  Leslie Citrome; Richard I G Holt; Daniel J Walker; Vicki Poole Hoffmann
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 6.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

Review 7.  Unanswered questions in schizophrenia clinical trials.

Authors:  John M Kane; Stefan Leucht
Journal:  Schizophr Bull       Date:  2008-01-16       Impact factor: 9.306

8.  Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

Authors:  Robert P McMahon; Deanna L Kelly; Douglas L Boggs; Lan Li; Qiaoyan Hu; John M Davis; William T Carpenter
Journal:  Schizophr Bull       Date:  2008-01-08       Impact factor: 9.306

9.  Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits.

Authors:  Luke E Sebel; Steven M Graves; C Savio Chan; D James Surmeier
Journal:  Neuropsychopharmacology       Date:  2016-08-31       Impact factor: 7.853

10.  Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice.

Authors:  José L Moreno; Terrell Holloway; Adrienne Umali; Vinayak Rayannavar; Stuart C Sealfon; Javier González-Maeso
Journal:  Psychopharmacology (Berl)       Date:  2012-07-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.